- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02511821
Elektronisk overvågningsanordning for patientrapporterede resultater og funktion til forbedring af patientcentreret pleje hos patienter med mave-tarmkræft, der gennemgår operation
Elektronisk overvågning af patientrapporterede resultater og funktion i GI-kræftkirurgi: En gennemførlighedsundersøgelse
This pilot clinical trial studies an electronic monitoring device of patient-reported outcomes (PROs) and function in improving patient-centered care in patients with gastrointestinal cancer undergoing surgery. Electronic monitoring is a technology-based way of asking patients about the quality of life, symptoms, and activity using online surveys and an activity tracking watch may make it easier for patients to tell their doctors and nurses about any issues before and after surgery. Electronic systems of assessing PROs may increase the depth and accuracy of available clinical data, save administrative time, prompt early intervention that improves the patient experience, foster patient-provider communication, improve patient safety, and enhance the consistency of data collection across multiple sites.
Studieoversigt
Status
Betingelser
- Stadie III Bugspytkirtelkræft
- Stadie IIA Kræft i bugspytkirtlen
- Stadie IIB Bugspytkirtelkræft
- Fase IV Mavekræft
- Stadie IVA tyktarmskræft
- Stadie IVA Kræft i bugspytkirtlen
- Stadie IVB Kolorektal cancer
- Stadie IVB Bugspytkirtelkræft
- Fase IIIA Mavekræft
- Fase IIIB Mavekræft
- Fase IIIC Mavekræft
- Stadie IA Kræft i bugspytkirtlen
- Stadie IB Kræft i bugspytkirtlen
- Fase IIA Mavekræft
- Fase IIB Mavekræft
- Stadie IVA leverkræft
- Stadie IVB leverkræft
- Fase I Kolorektal cancer
- Fase IIIA Kolorektal cancer
- Stadie IIIB Kolorektal cancer
- Stadie IIIC Kolorektal cancer
- Fase IA mavekræft
- Stadie IB mavekræft
- Fase IIA tyktarmskræft
- Stadie IIB Kolorektal cancer
- Fase IIC Kolorektal cancer
- Stadie I Voksen leverkræft
- Stadie II Voksen leverkræft
- Stadie IIIA Voksen leverkræft
- Stadie IIIB Voksen leverkræft
- Stadie IIIC Voksen leverkræft
Detaljeret beskrivelse
PRIMARY OBJECTIVES:
I. To determine the feasibility of administration of electronic patient-reported outcomes and functional assessment in gastrointestinal (GI) cancer surgery (gastric, colorectal, liver, pancreas).
II. Determine percentage of patients able to complete > 80% of MD. Anderson Symptom Inventory (MDASI) and European Quality of LIfe-5 Dimensions (EQ-5D) web-based surveys.
III. Determine percentage of patients able to wear the wristband device at least 1 week post-operatively.
IV. Determine length of time to complete the web-based surveys.
V. Determine length of time patients are able to wear the wristband device, before and after surgery.
SECONDARY OBJECTIVES:
I. Determine the percentage of patients who did not enroll in the study and analyze the reasons why. This will be accomplished using: 1) the number of patients asked to participate; 2) the number of patients who declined to participate, and 3) reasons for declining participation.
II. Responses from the Satisfaction Tool will be used to assess: 1) ease of use of web-based surveys and wristband device; 2) feedback on items in the web-based surveys that are distressing or difficult to comprehend; 3) feedback on length of surveys and timing of administration; and 4) suggestions for items that were not covered but should be added.
III. Calculate the mean number of missing items within each questionnaire to identify individual or subsets of questions that are difficult to answer.
OUTLINE:
Patients complete online surveys comprising questions about quality of life, symptoms, and activity level, and wear a wristband device (Vivofit watch) 3-7 days prior to and after surgery. After going home, patients complete the symptom survey three times a week and quality of life survey once a week for 2 weeks post-surgery.
After completion of study, patients are followed up for 1 month.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
California
-
Duarte, California, Forenede Stater, 91010
- City of Hope Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Scheduled to undergo surgery for primary or secondary gastric, colorectal, liver, or pancreas cancer
- Able to read and understand English
- Patients across all stages of disease
- There are no restrictions related to performance status or life expectancy
- This protocol is eligible for waiver of informed consent documentation; all subjects must have the ability to understand and the willingness to provide verbal informed consent
Exclusion Criteria:
- Research participants who have no computer and internet access and/or do not use a computer even if one is present in the household
- Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Enhedens gennemførlighed
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Supportive Care (Vivofit watch, online surveys)
Patients complete online surveys comprising questions about quality of life, symptoms, and activity level, and wear a wristband device (Vivofit watch) 3-7 days prior to and after surgery. After going home, patients complete the symptom survey three times a week and quality of life survey once a week for 2 weeks post-surgery. |
Ancillary studies
Andre navne:
Ancillary studies Complete online surveys Wear Vivofit watch
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Mean time patients are able to tolerate wearing the wristband device, both before and after surgery
Tidsramme: Up to 1 month
|
Descriptive statistics will be used to describe the distribution of time (before and after surgery) a patient is able to wear the wristband device. |
Up to 1 month
|
|
Mean time to complete the web based questionnaires MDASI and EQ-5D, as well as the Self Geriatric Assessment Measure
Tidsramme: Up to 1 month
|
Descriptive statistics will be used to describe the distribution of time to complete each assessment. |
Up to 1 month
|
|
Median time patients are able to tolerate wearing the wristband device, both before and after surgery
Tidsramme: Up to 1 month
|
Descriptive statistics will be used to describe the distribution of time (before and after surgery) a patient is able to wear the wristband device. |
Up to 1 month
|
|
Median time to complete the web based questionnaires MDASI and EQ-5D, as well as the Self Geriatric Assessment Measure
Tidsramme: Up to 1 month
|
Descriptive statistics will be used to describe the distribution of time to complete each assessment. |
Up to 1 month
|
|
Percentage of patients who are able to complete the web-based questionnaires MDASI and EQ-5D
Tidsramme: Up to 1 month
|
Descriptive statistics will be reported. Patients who complete at least 80% of all scheduled MDASI and EQ-5D questionnaires will be indicated as able to complete the web-based questionnaires. The true population proportion will be estimated with 95% confidence interval of half-width no more than 0.16. |
Up to 1 month
|
|
Percentage of patients who are able to wear the wristband device for at least 1 week post-operatively
Tidsramme: Up to 1 week post-operatively
|
Estimated with 95% confidence interval of half-width no more than 16%. |
Up to 1 week post-operatively
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Brugervenlighed for webbaserede undersøgelser og armbåndsenhed, målt ved svar fra Satisfaction Tool
Tidsramme: Op til 1 måned
|
Op til 1 måned
|
|
|
Feedback på emner i de webbaserede undersøgelser, der er foruroligende eller svære at forstå, målt ved svar fra Satisfaction Tool
Tidsramme: Op til 1 måned
|
Op til 1 måned
|
|
|
Feedback på længden af undersøgelser og timing af administration, målt ved svar fra Satisfaction Tool
Tidsramme: Op til 1 måned
|
Op til 1 måned
|
|
|
Forslag til emner, der ikke var dækket, men som bør tilføjes, målt ved svar fra Satisfaction Tool
Tidsramme: Op til 1 måned
|
Op til 1 måned
|
|
|
Mean number of missing items within each questionnaire
Tidsramme: Up to 1 month
|
Mean number of missing items within each questionnaire will be calculated to identify individual or subsets of questions that are difficult to answer. |
Up to 1 month
|
|
Percentage of patients who did not enroll in the study-composite outcome of multiple measure listed
Tidsramme: Up to 1 month
|
Percentage of patients who did not enroll in the study will be determined and the reasons why will be analyzed. This will be accomplished using: i) the number of patients asked to participate, ii) the number of patients who declined to participate, and iii) reasons for declining participation. |
Up to 1 month
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Virginia Sun, City of Hope Medical Center
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i det endokrine system
- Neoplasmer efter sted
- Neoplasmer
- Tarmsygdomme
- Neoplasmer efter histologisk type
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Mavesygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Neoplasmer i endokrine kirtler
- Pancreassygdomme
- Leversygdomme
- Neoplasmer, kirtel og epitel
- Adenocarcinom
- Tyktarmssygdomme
- Karcinom
- Neoplasmer i maven
- Carcinom, hepatocellulært
- Kolorektale neoplasmer
- Bugspytkirtel neoplasmer
- Neoplasmer i leveren
- Diagnostiske teknikker og procedurer
- Diagnose
- Overvågning, fysiologisk
Andre undersøgelses-id-numre
- 15051
- P30CA033572 (U.S. NIH-bevilling/kontrakt)
- 15051 (Anden identifikator: City of Hope Medical Center)
- NCI-2015-01061 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .